Rahman The Brain as a Drug Target

1. Auflage 2011
ISBN: 978-0-12-385507-7
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band Volume 98, 468 Seiten, Web PDF

Reihe: Progress in Molecular Biology and Translational Science

The brain is protected by the blood-brain barrier and this barrier prevents many drugs from entering the brain. This volume discusses various drug delivery and targeting strategies that are being developed to enhance the transport and distribution of drugs into the brain. - Discusses new discoveries, approaches, and ideas - Contributions from leading scholars and industry experts - Reference guide for researchers involved in molecular biology and related fields

Autoren/Hrsg.

Rahman, Shafiqur

Inhaltsverzeichnis

1;Front Cover;1
2;Progress in Molecular Biology and Translational Science: The Brain as a Drug Target;4
3;Copyright;5
4;Contents;6
5;Contributors;10
6;Preface;12
7;Chapter 1: Monoamine Transporters: Vulnerable and Vital Doorkeepers;16
7.1;I. Introduction;17
7.2;II. Clinical Benefits: Demonstration of the Medical Roles of Monoamine Transporters;18
7.3;III. Preclinical Indications-Behavioral Pharmacology ;21
7.4;IV. Molecular Study: cDNA Cloning and Structure Activity Relationship;26
7.5;V. Protein Regulations;29
7.6;VI. Animal Genetics;32
7.7;VII. The Transporter Genes as Risk Factors;35
7.8;VIII. Perspectives for Medication Development;39
7.9;Acknowledgments;42
7.10;References;42
8;Chapter 2: Therapeutic Targets in Alzheimer's Disease and Related Tauopathies;62
8.1;I. Introduction to the Disease;63
8.2;II. Attempts at Abeta Therapy;68
8.3;III. Tau Hypothesis;70
8.4;IV. Tau Theraputic Targets;81
8.5;V. Concluding Remarks;86
8.6;Acknowledgments;87
8.7;References;87
9;Chapter 3: Therapeutic Targets for Neuroprotection and/or Enhancement of Functional Recovery Following Traumatic Brain Injury;100
9.1;I. Introduction;101
9.2;II. Primary Injury Models;102
9.3;III. Receptor-Based Targets for Neuroprotection;104
9.4;IV. Targeting Enzymatic Activity for Neuroprotection;119
9.5;V. Other Promising Strategies;122
9.6;VI. Future Directions for Optimization of Treatment Regimens;129
9.7;References;131
10;Chapter 4: Insulin, Synaptic Function, and Opportunities for Neuroprotection;148
10.1;I. Introduction;149
10.2;II. Insulin Within the Central Nervous System;150
10.3;III. Insulin Receptors Within the Brain;155
10.4;IV. Insulin Signaling and Synaptic Function;163
10.5;V. Therapeutic Opportunities: Insulin and Neuroprotection;173
10.6;VI. General Summary;182
10.7;References;183
11;Chapter 5: Molecular Alterations in Glioblastoma: PotentialTargets for Immunotherapy;202
11.1;I. Introduction;203
11.2;II. Genetic Alterations in Glioblastoma;205
11.3;III. Ags and Biomarkers in Glioblastoma;210
11.4;IV. Ag-Specific Immunotherapy for Glioblastoma;217
11.5;V. Biomarker-Specific Chemotherapy for Glioblastoma;221
11.6;VI. Cytokine-Based Immunotherapy for Glioblastoma;227
11.7;VII. Chemoimmunotherapy for Glioblastoma;231
11.8;VIII. Tumor-Associated Molecules Influencing Glioblastoma Immunotherapy;233
11.9;IX. Conclusions;239
11.10;Acknowledgments;241
11.11;References;241
12;Chapter 6: Molecular Signaling and Translational Significance of the Corticotropin Releasing Factor System;250
12.1;I. Introduction to the Corticotropin Releasing Factor Peptide Family;251
12.2;II. Neural CRF Distribution;252
12.3;III. CRF Binding and Signal Transduction;256
12.4;IV. Genes and Gene Systems Activated by CRF;259
12.5;V. Interactions with Other Neural Circuits;262
12.6;VI. Translational Significance of CRF;268
12.7;VII. Integrated CRF Function;279
12.8;References;282
13;Chapter 7: Molecular Targets of Alcohol Action: Translational Research for Pharmacotherapy Development and Screening;308
13.1;I. Introduction;309
13.2;II. Alcohol Abuse and Dependence, Significance, and Treatment Needs;311
13.3;III. Preclinical Strategies for Identification of Novel Targets of Alcohol Action;312
13.4;IV. Translational Strategies and Need for Continued Biomarkers Development;342
13.5;References;346
14;Chapter 8: Brain Nicotinic Receptors as Emerging Targets for Drug Addiction: Neurobiology to Translational Research;364
14.1;I. Introduction;365
14.2;II. Brain nAChRs in Nicotine Addiction;366
14.3;III. Brain nAChRs in Alcohol Dependence;368
14.4;IV. Brain nAChRs in Other Addictive Disorders;370
14.5;V. Limitations in nAChR-Based Translational Research;372
14.6;VI. Conclusions and Future Perspectives;373
14.7;Acknowledgments;373
14.8;References;374
15;Chapter 9: Glutamatergic Neuroplasticity in Cocaine Addiction;382
15.1;I. Introduction;383
15.2;II. Neurocircuitry of Addiction;384
15.3;III. Adaptations in Synaptic Plasticity;388
15.4;IV. Glutamate Homeostasis Hypothesis of Cocaine Addiction ;393
15.5;V. Redox Regulation of Neurons;396
15.6;VI. Promise for Glutamate-Mediated Pharmacotherapies for Addiction;399
15.7;VII. Conclusion;404
15.8;References;404
16;Chapter 10: Role of the Serotonergic System in Alcohol Dependence: From AnimalModels to Clinics;416
16.1;I. Introduction;417
16.2;II. The Role of 5-HTT in Alcohol-Directed Neuroadaptation, Intoxication Response, and Potential for Abuse and Dependence;420
16.3;III. Serotonergic Receptors: Molecular, Pharmacological, and Physiological Aspects and Their Role in Alcohol Dependence;427
16.4;IV. Interactions Between the Serotonergic System and Other Neurotransmitter Systems in the Modulation of Alcohol Consumption;430
16.5;V. Serotonergic System as a Potential Therapeutic Target in Alcohol Dependence/Addiction;434
16.6;VI. Conclusions;441
16.7;Acknowledgments;442
16.8;References;442
17;Index;460
18;Color Plates;470